Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07VHU
|
|||
| Drug Name |
NIS793
|
|||
| Indication | Pancreatic ductal carcinoma [ICD-11: 2C10.0] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [2], [3] | ||
| Company |
Novartis Oncology East Hanover,
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transforming growth factor beta (TGFB) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04390763) Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.